Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
During the past 3 years, the average Book Value Per Share Growth Rate was -40.00% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -41.60% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.
During the past 9 years, the highest 3-Year average Book Value Per Share Growth Rate of Regenerative Medical Technology Group was 15.50% per year. The lowest was -57.50% per year. And the median was -22.05% per year.
Regenerative Medical Technology Group (OTCPK:RMTG) Book Value per Share Explanation
Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.
For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.
Regenerative Medical Technology Group Book Value per Share Related Terms
Regenerative Medical Technology Group Book Value per Share Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Regenerative Medical Technology Group Book Value per Share Chart
RMTG vs ABPO, CLSDQ, SCNI: Book Value per Share Comparison
For the Biotechnology subindustry, Regenerative Medical Technology Group's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Regenerative Medical Technology Group PB Ratio vs Biotechnology Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Regenerative Medical Technology Group (RMTG) has a Book Value per Share of $-2.71 as of Mar. 2026. Book value per share gives the per-share value of a company's stockholder equity. View historical data on Regenerative Medical Technology Group and its competitors.
Is Regenerative Medical Technology Group's Book Value per Share too high?
Regenerative Medical Technology Group's current Book Value per Share is $-2.71.
How does Regenerative Medical Technology Group's Book Value per Share compare to ABPO and CLSDQ?
Regenerative Medical Technology Group's Book Value per Share of $-2.71 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Book Value per Share for a Biotechnology company?
A good Book Value per Share depends on the Biotechnology industry context. However, Book Value per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Book Value per Share mean?
A high Book Value per Share can signal that a stock is expensive relative to its fundamentals. Book value per share gives the per-share value of a company's stockholder equity. View historical data on Regenerative Medical Technology Group and its competitors. Regenerative Medical Technology Group's current Book Value per Share is $-2.71. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Regenerative Medical Technology Group stock overvalued right now?
Based on GuruFocus' analysis, Regenerative Medical Technology Group (RMTG) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.06, compared to a current price of $0.10 — trading 60.3% above its estimated fair value. The current Book Value per Share is $-2.71. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Book Value per Share calculated?
Book Value per Share is calculated from a company's financial statements. For Regenerative Medical Technology Group (RMTG), the current Book Value per Share is $-2.71 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Regenerative Medical Technology Group Business Description
Regenerative Medical Technology Group Inc is engaged in the regenerative medicine business through its subsidiary, Global Stem Cells Group. The company provides stem cell therapies, exosomes, peptides, biologics, physician training and certifications, diagnostic tools, and related clinical support services. It operates through one reportable segment, Global Stem Cells Group.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RMTG has been successfully added to your 
